Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy
- 1 October 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (10), 3710-3717
- https://doi.org/10.1128/aac.00364-08
Abstract
Development of a safe, effective, and inexpensive therapy for African trypanosomiasis is an urgent priority. In this study, we evaluated the validity of Trypanosoma brucei glycogen synthase kinase 3 (GSK-3) as a potential drug target. Interference with the RNA of either of two GSK-3 homologues in bloodstream-form T. brucei parasites led to growth arrest and altered parasite morphology, demonstrating their requirement for cell survival. Since the growth arrest after RNA interference appeared to be more profound for T. brucei GSK-3 “short” (Tb10.161.3140) than for T. brucei GSK-3 “long” (Tb927.7.2420), we focused on T. brucei GSK-3 short for further studies. T. brucei GSK-3 short with an N-terminal maltose-binding protein fusion was cloned, expressed, and purified in a functional form. The potency of a GSK-3-focused inhibitor library against the recombinant enzyme of T. brucei GSK-3 short, as well as bloodstream-form parasites, was evaluated with the aim of determining if compounds that inhibit enzyme activity could also block the parasites' growth and proliferation. Among the compounds active against the cell, there was an excellent correlation between activity inhibiting the T. brucei GSK-3 short enzyme and the inhibition of T. brucei growth. Thus, there is reasonable genetic and chemical validation of GSK-3 short as a drug target for T. brucei . Finally, selective inhibition may be required for therapy targeting the GSK-3 enzyme, and a molecular model of the T. brucei GSK-3 short enzyme suggests that compounds that selectively inhibit T. brucei GSK-3 short over the human GSK-3 enzymes can be found.Keywords
This publication has 34 references indexed in Scilit:
- Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKsStructure, 2007
- Inhibition of neuronal apoptosis by the cyclin‐dependent kinase inhibitor GW8510: Identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugsJournal of Neurochemistry, 2005
- Structure‐Aided Optimization of Kinase Inhibitors Derived from AlsterpaulloneChemBioChem, 2005
- A doubly inducible system for RNA interference and rapid RNAi plasmid construction in Trypanosoma bruceiMolecular and Biochemical Parasitology, 2004
- A Facile Method for High-throughput Co-expression of Protein PairsMolecular & Cellular Proteomics, 2004
- Inhibitors of Leishmania mexicana CRK3 Cyclin-Dependent Kinase: Chemical Library Screen and Antileishmanial ActivityAntimicrobial Agents and Chemotherapy, 2004
- The Trypanosoma brucei Cyclin, CYC2, Is Required for Cell Cycle Progression through G1 Phase and for Maintenance of Procyclic Form Cell MorphologyPublished by Elsevier BV ,2004
- Stage-specific Differences in Cell Cycle Control in Trypanosoma brucei Revealed by RNA Interference of a Mitotic CyclinJournal of Biological Chemistry, 2003
- GSK3 takes centre stage more than 20 years after its discoveryBiochemical Journal, 2001
- Glycogen synthase kinase-3: functions in oncogenesis and developmentBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1992